ClinicalTrials.gg
CompletedNCT01217671Updated Nov 29, 2019

International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema

A Phase 2/3 interventional study of Kamada AAT for inhalation and Placebo in Emphysema, sponsored by Kamada, Ltd.. Completed at 12 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Kamada, Ltd. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Emphysema with a site in United Kingdom — 4 open to participants now, 7 under way, none of them phase 3. Emphysema · United Kingdom.

Enrollment
11th of 35
168 · median 73
Started
2009
with 2 others
Phase 2/3
Only one
of the 46
Registered
15th of 46
by date

Among the 46 studies in Emphysema with a site in United Kingdom, this one is the 11th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2009, is the only one in phase 2/3, and was the 15th registered.

Emphysema

382 studies on the registry are indexed under Emphysema; 58 are open to participants now.

Browse Emphysema studies →

Open to participants now

4 of the 46 studies in Emphysema with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 49 Emphysema studies recruiting now, 27 (55%) set no upper age limit and 8 (16%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Emphysema with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a randomised , placebo controlled, double blind , multicentre, Phase II/III study evaluating the safety and efficacy of Kamada AAT for inhalation in patients with Emphysema caused by Alpha-1 Antitrypsin (AAT) deficiency.

Read the detailed description

Alpha-1 Antitrypsin Deficiency, also called Alpha-1-Proteinase Inhibitor (API) deficiency, is a genetic disorder characterized by the production of an abnormal amount of AAT protein and reduced circulating levels of this protein. Subjects with AAT deficiency are at increased risk for developing Emphysema. It is believed that this is the result of the chronic activity of elastase released by cells continually present in the lungs in low numbers.

Three blinded interim analyses have shown that there are no safety issues and no concerns regarding tolerability.

03

Conditions studied

  • Emphysema

Keywords

  • Pulmonary, Emphysema
  • Alpha-1 Antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Principal Inclusion Criteria:

  • Diagnosis of emphysema confirmed by CT scan. If a report of past CT scan is not available at site documenting then a CT scan is to be performed at screening
  • Male or female patients at least 18 years of age.
  • Able and willing to sign an .
  • Patient with record of congenital AAT deficiency of phenotype PiZZ (homozygote) or other rare phenotypes related to AAT deficiency and with AAT serum level ≤ 11 micromole. For patients receiving IV AAT augmentation therapy the serum AAT level threshold does not apply.
  • /SVC \<70% of predicted value post bronchodilator (SVC is slow VC) and FEV1 \< 80% of predicted value post-bronchodilator
  • History of at least two moderate or severe exacerbations that required change in treatment (antibiotics, systemic , hospitalization) in the last 18 months prior to date of screening , with at least one of these occurring within the last 12 months prior to screening.
  • Ability to comply with completion of electronic diary.
  • Ability to self-administer inhaled AAT.
  • No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.
  • No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.
  • No significant abnormalities in per investigator judgment.
  • Negative for and for antibodies to , -1.
  • AAT deficient patients who are either naïve (not receiving IV augmentation therapy) or AAT deficient patients (receiving IV augmentation therapy), if they have been stable on regular therapy for at least 3 months prior to the screening visit and are willing to continue the same regime throughout this trial. Note that only sites in Germany can recruit patients who are currently being treated with IV AAT.Patients who stopped IV augmentation treatment 6 months prior to screening date and will not re-start this treatment for the course of the study will be considered Naïve.
  • Non-pregnant, non-lactating female patients, whose screening pregnancy test is negative and who are using methods deemed reliable by the investigator, or who are at least 2 years or surgically sterilized.

Principal Exclusion Criteria:

  • FEV1 >= 80% or FEV1 \< 20% of predicted value post-bronchodilator.
  • FEV1/SVC>=70%
  • History of lung transplant.
  • Any lung surgery within the past two years.
  • On any thoracic surgery waiting list.
  • End of last exacerbation less than 6 weeks prior to screening/re-screening visit.
  • intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor.
  • Active smoking during the last 12 months from screening date.
  • Pregnancy or lactation.
  • Woman of not taking adequate contraception deemed reliable by the investigator.
  • Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give informed consent or to comply with the requirements of the study protocol.
  • Evidence of ongoing viral infection with HCV, HBV and/or HIV.
  • Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs.
  • IgA Deficiency
  • History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products.
  • Participation in another clinical trial within 30 days prior to baseline visit.
  • Inability to attend scheduled clinic visits and/or comply with the study protocol.
  • Any other factor that, in the opinion of the investigator, would prevent the patient from complying with the requirements of the protocol.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Alpha-1 Antitrypsin

    Biological: Kamada AAT for inhalation

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalKamada AAT for inhalation

    Alpha-1 Antitrypsin (AAT)

    Also known as: Alpha-1 Proteinase Inhibitor (API)

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Exacerbation events and lung density

    Time frame: Approximately 1 year

Secondary outcomes

  1. Adverse Events

    Time frame: Approximately 1 year

  2. Vital Signs

    Time frame: Approximately 1 year

  3. Physical Examination

    Time frame: Approximately 1 year

  4. ECG

    Time frame: Approximately 1 year

  5. Lung function

    Time frame: Approximately 1 year

  6. Laboratory Evaluations

    Time frame: Approximately 1 year

07

Study locations

12 sites
  • Inspiration Research Limited
    Toronto, Canada
  • Seymour Health Centre
    Vancouver, Canada
  • Gentofte Hospital
    Hellerup, Denmark
  • Universitätsklinikum des Saarlandes
    Homburg/Saar, Germany
  • Universitatsklinikum Gieben und Marburg
    Marburg, Germany
  • Beaumont Hospital
    Dublin, Ireland
  • LUMC
    Leiden, Netherlands
  • Malmo University Hospital
    Malmo, 20502, Sweden
  • Karolinska Universitetssjukhuset Solna
    Stockholm, Sweden
  • Queen Elizabeth Hospital
    Birmingham, United Kingdom
  • Royal Infirmary of Edinburgh
    Edinburgh, United Kingdom
  • Royal Brompton Hospital
    London, United Kingdom
08

References and documents

Publications

  • Stolk J, Tov N, Chapman KR, Fernandez P, MacNee W, Hopkinson NS, Piitulainen E, Seersholm N, Vogelmeier CF, Bals R, McElvaney G, Stockley RA. Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019 Nov 21;54(5):1900673. doi: 10.1183/13993003.00673-2019. Print 2019 Nov. PubMed 31467115 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Nov 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2010
First posted
Oct 8, 2010
Start
Dec 2009
Primary completionActual
Nov 2014
CompletionActual
Jun 2015
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01217671
Lead sponsor
Kamada, Ltd.
Responsible party
Sponsor
First posted
Oct 8, 2010
Start date
Dec 2009
Primary completion
Nov 2014
Completion
Jun 2015
Last update
Nov 29, 2019

Study contacts

Jan Stolk, Professor
principal investigator · LUMC, Leiden, Netherlands

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion